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A novel preference-informed
complementary trial (PICT) design for
clinical trial research influenced by strong
patient preferences
Samina Ali1,2* , Gareth Hopkin3, Naveen Poonai4, Lawrence Richer1, Maryna Yaskina2, Anna Heath5,6,7,
Terry Paul Klassen8,9, Chris McCabe3, on behalf of the KidsCAN PERC Innovative Pediatric Clinical Trials No OUCH
Study Group and the KidsCAN PERC Innovative Pediatric Clinical Trials Methods Core

Abstract
Background: Patients and their families often have preferences for medical care that relate to wider considerations
beyond the clinical effectiveness of the proposed interventions. Traditionally, these preferences have not been
adequately considered in research. Research questions where patients and families have strong preferences may
not be appropriate for traditional randomized controlled trials (RCTs) due to threats to internal and external validity,
as there may be high levels of drop-out and non-adherence or recruitment of a sample that is not representative of
the treatment population. Several preference-informed designs have been developed to address problems with
traditional RCTs, but these designs have their own limitations and may not be suitable for many research questions
where strong preferences and opinions are present.
Methods: In this paper, we propose a novel and innovative preference-informed complementary trial (PICT) design
which addresses key weaknesses with both traditional RCTs and available preference-informed designs. In the PICT
design, complementary trials would be operated within a single study, and patients and/or families would be given
the opportunity to choose between a trial with all treatment options available and a trial with treatment options
that exclude the option which is subject to strong preferences. This approach would allow those with strong
preferences to take part in research and would improve external validity through recruiting more representative
populations and internal validity. Here we discuss the strengths and limitations of the PICT design and
considerations for analysis and present a motivating example for the design based on the use of opioids for pain
management for children with musculoskeletal injuries.
Conclusions: PICTs provide a novel and innovative design for clinical trials with more than two arms, which can
address problems with existing preference-informed trial designs and enhance the ability of researchers to reflect
shared decision-making in research as well as improving the validity of trials of topics with strong preferences.
Keywords: Clinical trial, Patient preference, Methodology, Caregiver preference
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Background
Patients and families are often presented with treatment
options that require them to consider the efficacy of
treatments, their personal preferences, and the values
and weight they place on health outcomes [1]. In clinical
practice, patients, families, and clinicians can work towards shared decision-making that achieves a balance
between effectiveness and preferences [2]. However, in
research, patients and families must choose whether to
give consent and receive an allocated treatment or be
excluded. This can pose problems for research both
ethically (i.e., shared decision-making) and practically
(i.e., study feasibility, validity).
Preferences in healthcare arise for a number of reasons
and reflect patients’ and families’ personal values regarding treatment options. When they are strongly held,
preferences may drive treatment decisions regardless of
the effectiveness of treatments and consideration of preferences is crucial to effective shared decision-making
[1]. Awareness of patient preferences and their importance has increased over recent years, but there is often
still a mismatch between what health professionals believe patients value and what they actually value [3]. In
research, there is still limited focus on patient preferences and novel approaches are needed to ensure that
preferences are considered when planning studies.
Preference-informed trial designs

Randomized controlled trials (RCTs) are considered the
gold standard of effectiveness research and are the design of choice for comparing interventions in healthcare
[4]. However, when patients have strong preferences that
directly influence treatment decisions, the traditional
RCT design may be problematic. The external validity of
trials relies on recruiting a sample which is representative of the patient group as a whole. Where strong preferences are present, traditional RCTs may be unable to
recruit patients who would not accept random allocation
to an intervention, and this may lead to unrepresentative
samples or could undermine trial feasibility. Additionally, the internal validity of trials relies on randomized
patients having similar adherence to treatment options
and retaining patients for the duration of follow-up in
the trial. Where strong preferences are present, patients
may drop out or cross-over if they receive an intervention they do not want or feel uncomfortable about being
blinded.
Some attempts to adapt the RCT design have been
made [5] with preferences recorded after consent but
prior to randomization and this information being used
in analyses to explore whether treatment effects differ
according to preference. When preferences are not
strongly held, this approach has been acceptable [6], but
where preferences are more strongly held, innovative
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trial methods are needed to ensure representative samples are recruited and retained. Partially randomized
preference trials and doubly randomized preference
trials have both been developed to incorporate consideration of preferences, but for both designs, there are outstanding issues [6, 7].
In partially randomized preference trials, patients who
wish not to be consented to randomization are able to
opt for their preferred treatment while patients without
strong preferences are randomized using traditional
methods [6, 8]. This approach addresses some concerns
regarding external validity as patients with strong preferences are still able to take part in the research. It also
may help with issues of internal validity if participants
have higher levels of adherence and can be retained in
greater numbers at follow-up. However, this method introduces biases that may limit its use. Patients who
choose to select their treatment rather than being randomized become an observational cohort with the potential for high levels of selection bias. This limits the
validity of including these participants in pooled analyses
with randomized participants, and this analytic approach
cannot address issues of bias. Furthermore, there are
practical challenges in using this approach with some research questions. If only one of multiple treatment options is subject to strong preferences, there is the
possibility that only a small number of patients would
opt for randomization or for one of the treatments. This
would lead to the loss of the randomization element of
the trials and introduce an imbalance across preference
arms leaving it of little value.
A recently published partially randomized preference
trial adopted this approach after initial problems with
recruiting for a traditional RCT [9]. Recruitment rates
increased after investigators allowed participants to
choose either traditional randomization or their preferred treatment (i.e., ambulatory or inpatient care) for
severe nausea and vomiting of pregnancy. Data from
both randomized and preferred treatment arms were
pooled for analysis, but this approach seems undermined
by a difference between the characteristics of the groups
at baseline. For the primary outcome, those choosing inpatient treatment had the highest nausea/vomiting score
in the four groups, and those choosing the outpatient
treatment had the lowest score. The issues presented by
these differences and their impact on the results were
not fully explored. Indeed, the use of a partially randomized preference trial design improved recruitment rates
and external validity, but worsened threats to internal
validity.
Another option for preference-informed trials is the
doubly randomized preference trial design. In this design, patients are randomized either to a random group
with conventional randomization to intervention arms
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or to a choice group where they are able to choose their
intervention [7]. This approach may help to address issues of internal validity as participants in the random
and choice groups should be similar, but nonetheless issues of selection bias may remain within the choice
group [10]. The doubly randomized preference trial design may increase the number of patients who choose to
consent as there is a lower chance that they may be ultimately randomized to a less preferred treatment. However, in research questions with strong preferences, a
number of patients may still be unwilling to consent to
this. This can translate to problems with external validity
that are also seen in traditional RCTs.
In an example of a doubly randomized preference
trial, Zoellner et al. [11] examined the comparative
effectiveness of prolonged exposure to triggers of
traumatic stress compared to sertraline for the treatment of post-traumatic stress disorder and randomly
allocated participants to a random assignment group
or a choice group. From the outset, they expected a
preference for prolonged exposure and high levels of
drop-out and non-adherence in the sertraline group.
These expectations were borne out, and threats to internal validity were introduced with many more participants in the choice arm selecting prolonged
exposure than sertraline. In addition, there were low
levels of adherence and high levels of drop-out, particularly for the randomized to sertraline groups.
From the trial reporting, it is difficult to ascertain the
proportion of eligible participants who gave consent,
but it seems plausible that those with the strongest
aversion to medication and/or desire for prolonged
exposure would not be included in the study, raising
similar issues of external validity that one might expect with a traditional randomized clinical trial.
Both of these preference-informed trial approaches
are useful in some circumstances, but there continues
to be a need for novel innovative designs for research
questions where there are strongly held preferences
which will have a large impact on the behavior of eligible patients. In this paper, we propose a novel and
innovative design for comparative effectiveness trials
which include three treatment options and a patient
group who may have a strong aversion to one of the
treatment options. This innovative design for clinical
trials with more than two arms was motivated by a
comparative effectiveness trial of pain medications in
the emergency department for pediatric musculoskeletal (MSK) injury where families often have a strong
preference to avoid opioids [12, 13]. This design
could improve both internal and external validity
compared to traditional randomized controlled trials
and existing preference-informed trial designs. In
addition, it would respect values of shared decision-
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making and patient and caregiver autonomy in the research setting and could give real-world insights into
the impact of preference on treatment decisions.

A novel preference-informed complementary trial
(PICT) methods
Design

The preference-informed complementary trial (PICT)
design is a method that has been designed to allow patient and caregivers’ preferences to be reflected within
the research context and to address the methodological
limitations of other preference-informed designs. The
design relies on two complementary trials being implemented within a single study and allows patients/caregivers to select between trials at the same entry point.
The complementary trials are designed as collaborative
trials and would function in parallel to avoid duplication
of effort and resources that would be needed to provide
the trials separately.
In the PICT design, patients and families are asked
whether they would prefer to participate in one of two
simultaneously occurring complementary, or ‘sister,’ trials (see Fig. 1). These two trials contain differing numbers of interventions, with one trial including all possible
interventions and one trial excluding the intervention
that is subject to strong preferences, allowing patients
and families to be included in research but to avoid a
specific treatment option. After patients and families
have chosen the trial based on their preference, they are
randomized to the interventions included in the trial of
their choice. Trial procedures from traditional randomized controlled trials are then followed, with the two
complementary trials sharing identical procedures, and
running in parallel, until the completion of both trials.
The use of two complementary trials allows those who
have a strong preference to avoid a particular treatment
option while still being randomized to the other available treatment arms. It is envisaged that this approach
could lead to all patients being pooled in a single analysis, if statistically and clinically appropriate, which
would lead to increased power and improved
generalizability.
Analysis

The populations in the complementary trials may be different, as they do not have the same preferences. If these
preferences do NOT influence the treatment effect, then
the two trials could be analyzed together to estimate the
single common treatment effect. This would improve
the power of the study and our ability to generalize
study results to different patient populations. In PICT
trials, a family’s expression of preference is, by definition,
measured at baseline (i.e., at the time of recruitment).
Randomization should, in theory, allow for equal
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Fig. 1 Schema of the PICT design using a pooled analysis. Participants would be asked to choose between two trials with Trial 2 containing all
three treatment options (A, B, C) and Trial 1 containing two treatment options (A, B) and omitting the option with strong preferences that may
deter participation (C). Participants would then be randomized to the available treatment options according to their choice of trial. If there is no
clinical or statistical evidence that trial populations have important differences, then data from all arms can be pooled for a single analysis

distribution of all other unknown variables between the
populations, so long as they are not conditional on preference, as preference of trial choice is the only factor
that influences the probability of receiving any one of
the treatments at the time of randomization. However,
to erroneously estimate a single treatment effect would
lead to biased, potentially imprecise, and thus misleading
results. To mitigate this potential risk, we propose that a
single treatment effect should be estimated within PICTs
unless there is clinical or statistical evidence of an important, fundamental difference between the two populations, with a separate treatment effect estimated for
each trial as a sensitivity analysis.
We suggest that the clinical rationale for estimating a
single treatment effect should focus on whether the
baseline characteristics across the complementary trials
are similar based on clinical meaningfulness and acceptability to knowledge users. In order to determine this,
we will engage clinicians to indicate the level of differences in baseline characteristics of the two complementary trials that would be seen as acceptable for
estimating a single treatment effect. To minimize the
bias in this decision-making, pre-specified decision rules
should determine a maximum tolerated difference between the trials for each of the baseline characteristics
and these decisions should be guided by feasibility and
pilot studies. It is possible that several patient characteristics could strongly influence the preference for one
treatment over another; however, if there is clinical rationale that these cannot be effect modifiers, then they
can be excluded. If a clinical rationale for estimating a

single treatment effect has been established, we suggest
a formal statistical testing procedure to determine
whether there is statistical evidence that the complementary trials should be analyzed separately. This statistical testing should assess whether there is a statistically
significant difference between the treatment effects for
the primary outcome across the trials. Only if there is no
evidence, statistically or clinically, for a different treatment effect across trials should a single treatment effect
estimate be provided. By including a statistical and clinical testing procedure, we will ensure that the analysis of
the PICT will be acceptable within the clinical community, even in the settings where the test of significance
for the trial by treatment interaction is underpowered.
The analysis plan for PICTs should include details on
both the clinical and statistical testing procedures that
will be used. It is advisable that the analysis plan outlines
the analytical procedures that would be followed in both
cases, with and without a single treatment effect. Separate analysis of the two trials should also be included as a
supplementary analysis, if the primary analysis focuses
on estimating a single treatment effect.
Sample size considerations

As the analysis for PICTs may require a separate analysis
for each trial, we suggest that they are powered separately. This means that the sample size requirements for
PICTs are larger than a standard RCT. We also recommend that the recruitment rates into each trial are monitored closely, with potential adjustments made if
required to ensure the feasibility of the trials, i.e.,
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stopping a trial early or changing randomization ratios
to ensure enough patients receive the intervention that
is subject to strong preferences. The impact of these adjustments on the statistical power of the individual trials
should be assessed and reported clearly.

Discussion
Motivating example

Our research team wished to examine pain management
options for children with MSK injury [14–16]. Ibuprofen
has been established as first-line therapy for acute MSK
pain, but is often inadequate in isolation [15, 17, 18]. As
such, there was a need to identify an adjuvant medication to augment the analgesia provided by ibuprofen. An
opioid, oral hydromorphone, has been shown to be effective in other contexts [19, 20] and is appropriate as a
candidate for comparison to other non-opioid analgesic
options (ibuprofen; ibuprofen + acetaminophen). The
addition of acetaminophen to ibuprofen was included
because it has been shown to be effective for other patient groups [19, 20] and, if shown to have a similar
additive efficacy in this setting, would be a non-opioid
option. Despite the known effectiveness of opioids for
moderate to severe pain [21], the opioid crisis in North
America means that many patients and families may
have strong preferences to avoid opioids. Deaths from
opioids in the USA and Canada have reached epidemic
levels [22, 23], and media, third sector, and health service responses have increased the salience of the dangers
of non-medical use of opioids [24]. Due to this, along
with the unknown risk of developing opioid use disorders after short-term therapeutic use, families may want
to avoid exposure to opioids in a clinical trial regardless
of their potential effectiveness; recent empirical work
supports this notion and has suggested that less than
50% of caregivers would accept opioids for moderate
pain after MSK injury [13].
Due to this opioid reluctance, it was decided that a
traditional RCT and a doubly randomized preference
trial would have low recruitment rates. Similarly, a partially randomized controlled trial may have limited recruitment to the randomized group and an imbalance
between caregivers choosing against oral hydromorphone. Due to these limitations, the PICT approach was
conceived for the Non-Steroidal or Opioid Analgesia
Use for Children with Musculoskeletal Injuries (No
OUCH) study which began recruitment in early 2019
(ClinicalTrials.gov Identifier: NCT03767933) [25].
In the No OUCH PICT, caregivers are asked whether
they would like to participate in a 3-arm trial which includes all possible treatment options (oral ibuprofen +
oral hydromorphone; oral ibuprofen alone; oral ibuprofen + oral acetaminophen) or a 2-arm trial arm which
does not include the opioid treatment (oral ibuprofen
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alone; oral ibuprofen + oral acetaminophen). This approach allows caregivers who would be reluctant to take
part in the trial if there was a chance of receiving opioids
to be included, allowing caregivers’ opioid preferences to
be reflected in the research design.
Our motivating example will also embed a preference
survey into the study to examine whether families’ characteristics, prior experience with opioid treatment or
substance misuse, or source of injury differ according to
preference. A qualitative sub-study will also use interviews to further understand caregiver decision-making.
To determine whether the two trials have clinically different baseline characteristics, we will evaluate these
characteristics at the interim analysis at the mid-point of
the No OUCH trials. We will tabulate these baseline
characteristics as though they are to be included in the
final report. We will then ask a group of experts whether
they think the results of a trial in one of these populations are relevant to the other. If they do not believe the
two populations are similar, based on this interim analysis, then a discrete choice experiment will be undertaken within the Pediatric Emergency Research Canada
network to determine a formal rule for pooling. Statistical testing for different treatment effects across the two
trials will be undertaken using nested linear mixed
models. Specifically, the full model will include a treatment by trial interaction term while the reduced model
will only include two treatment effect parameters. A
likelihood ratio test will be used to declare whether the
treatment by trial interaction is significant.
Both trials have a power of 90% to detect the treatment effect, with sample sizes of 170 and 315 for the
two- and three-arm trials, respectively, giving a power
for the combined analysis of 98%. Thus, the minimum
sample size of the No OUCH PICTs is 1.54 times higher
than the equivalent three-arm trial. The No OUCH trials
also include an interim assessment of the recruitment
rates into the two trials. Thus, the sample size may
change as we could increase the proportion of patients
randomized to oral ibuprofen + oral hydromorphone in
the three-arm trial if there is a high imbalance in recruitment rates, provided that the power of the three-arm
trial remains above 80% [26]. If the treatment by trial
interaction is not significant, then the trials will also be
analyzed separately as sensitivity analyses (Fig. 2). If
there is clinical or statistical evidence that the treatment
effect is not the same across the two trials, indicating
confounding or effect modification, then the trials will
re-analyzed and reported separately (Fig. 3). In both
eventualities, the PICT approach is superior to traditional RCTs or other preference-informed trials. On the
one hand, if no differences exist, recruitment will have
been maximized. On the other hand, if differences do
exist, then a group who would have not otherwise been
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Fig. 2 Schema of the No OUCH trials using a pooled analysis. Participants would be asked to choose between two trials with the opioid-inclusive
trial containing all three treatment options (ibuprofen; ibuprofen + acetaminophen; ibuprofen + hydromorphone) and non-opioid trial containing
non-opioid options (ibuprofen; ibuprofen + acetaminophen) and omitting the opioid option with strong preferences that may deter participation
(ibuprofen + hydromorphone). Participants would then be randomized to the available treatment options according to their choice of trial. If
there is no clinical or statistical evidence that trial populations have important differences, then data from all arms can be pooled for a
single analysis

recruited will be included in the study. The complete
statistical analysis plan is published and available for
reference [26].
Strengths and limitations of the preference-informed
complementary trials design

A key advantage of the PICT design is that it allows patients with a strong preference to avoid a particular
treatment and still participate in the research process,

thereby increasing the external validity of the trial. In
the No OUCH study, it is anticipated that more caregivers will agree to participate in the study than if we
ran a single trial with an opioid arm. This will improve
the external validity by increasing the number of eligible
participants enrolled in the study compared to other trial
methodologies.
The PICT design can also improve internal validity by
reducing drop-out, poor adherence, and cross-over by

Fig. 3 Schema of the No OUCH trials using a separate analysis. Participants would follow the procedure described in Fig. 2, but if important
clinical and statistical differences were found between trial populations which prevented pooling, then they would be analyzed separately and
alternative methods for synthesizing the results of the trial would be used
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allowing patients to avoid treatment options to which
they have a strong aversion or to select a trial with more
favorable options. These issues would not be seen in the
motivating No OUCH trial due to the immediacy of the
intervention and short-term outcomes (i.e., oral administration at randomization and change in pain score at 60
min). However, in trials with different treatment modalities (i.e., pharmacologic and psychological arms), this
may be particularly important.
Another benefit of the PICT design is that a larger
number of eligible patients and families are included in
the research. This allows for a quantitative and qualitative exploration, in a more representative sample, of why
strong preferences for different treatment options are
present. This mixed methods approach could ensure
that as much information as possible is learned from
trial-based research [27]. In cases where effectiveness
may differ according to preferences, this will also provide valuable information to improve understanding of
treatment mechanisms and responses in real-world
scenarios.
There are threats to internal validity with the PICT design. If preferences are driven by or associated with confounders or effect modifiers, pooled analyses are not
appropriate. For example, in the No OUCH trial, if preferences lead to substantial differences in age, pain score
at baseline, or type of injury, then pooling would not be
appropriate as these variables could be confounders or
effect modifiers. This issue also affects partially randomized preference trials. In the PICT design, the population
with strongly held preferences will be included in the
study and will still be randomized to the treatment options which they are willing to receive. Thus, the PICT
design still determines the best treatment option for this
group and can guide decisions in the real world where
clinicians face questions about the most effective treatment for those with strong treatment preferences.
In the No OUCH study, the two complementary trials
are powered to detect a difference within the trial and
recruitment will need to continue into both trials until
recruitment targets are met. This means that a greater
number of participants compared to a traditional 3-arm
randomized trial would be needed, with overrecruitment of the 2-arm trial. Thus, a PICT trial may
take longer and be more resource intensive than other
trial designs. However, the benefits of using the PICT
design will often outweigh these concerns and provide
more comprehensive analysis across a spectrum of research questions. A PICT design will also guard against
loss of validity if a high level of patients decline to be exposed to a particular treatment option. In addition, the
cost of recruiting additional participants or delivering
additional interventions may be limited compared to the
resources needed to set up and deliver a second separate
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clinical trial of any size. The PICT design is a proposed
solution to the problem of patient preferences making a
trial unfeasible. Hence, while a larger sample size may
extend the recruitment period for a PICT trial, we would
only expect this trial design to be employed when a conventional trial design is deemed unfeasible.

Conclusions
In healthcare, patients and families may have strong
preferences about the treatments they receive that go beyond considerations of efficacy. When interventions have
such preferences attached, traditional RCTs and
preference-informed designs have issues with internal
and external validity that need to be addressed. The
novel and innovative preference-informed complementary trial (PICT) design can address these issues while
also allowing patients’ and families’ values to be reflected
and understood in research and ensure trial funding is
used efficiently. In our motivating example, a multiarmed trial with opioids in acute pain for MSK injury,
the PICT is the preferable design. It allows patient and
family preferences to be reflected and understood in research. It also ensures that recruitment is maximized
and questions that are relevant to clinical practice can
be answered in a timely manner. Many other research
questions could benefit from this approach, which addresses issues with both internal and external validity.
Thus, research in areas with strong preferences should
consider this design alongside traditional RCTs and
other preference-informed designs. The No OUCH trial
will provide information on the implementation of PICT
trials and will provide guidance to support teams who
wish to replicate this approach in future studies.
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